The pharmaceutical industry is facing difficult challenges in its global business environment, requiring companies to
fundamentally re-think their strategies, approaches to the market and investment decisions. Globalisation of
markets, the ease of global communications and the existence of an increasingly international and mobile pool of
scientific and commercial talent mean that companies can serve more markets from fewer locations. Companies
have more choice than ever before when deciding where to locate new investments and we are operating in a
turbulent environment where there is increasing pressure to contain costs. These are all factors driving current
global investment decisions.